Afatinib restrains K-RAS driven lung tumorigenesis

Based on clinical trials using first generation EGFR tyrosine kinase inhibitors (TKI) it became a doctrine that K-RAS mutations drive resistance to EGFR inhibition in non-small cell lung cancer (NSCLC). Conversely, we provide evidence that EGFR signaling is engaged in K-RAS driven lung tumorigenesis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Transl Med
Autors principals: Moll, Herwig P., Pranz, Klemens, Musteanu, Monica, Grabner, Beatrice, Hruschka, Natascha, Mohrherr, Julian, Aigner, Petra, Stiedl, Patricia, Brcic, Luka, Laszlo, Viktoria, Schramek, Daniel, Moriggl, Richard, Eferl, Robert, Moldvay, Judit, Dezso, Katalin, Lopez-Casas, Pedro P., Stoiber, Dagmar, Hidalgo, Manuel, Penninger, Josef, Sibilia, Maria, Győrffy, Balázs, Barbacid, Mariano, Dome, Balázs, Popper, Helmut, Casanova, Emilio
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7610658/
https://ncbi.nlm.nih.gov/pubmed/29925635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aao2301
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars